Review Article
Inflammation-Based Scores: A New Method for Patient-Targeted Strategies and Improved Perioperative Outcome in Cancer Patients
Table 3
Published studies about platelet-to-lymphocyte ratio (PLR).
| Author | Cancer type | Study nature | Cutoff | Outcome |
|
Bhatti et al. [93] | Pancreatic | Retrospective | <100 100–200 >200 | No correlation between PLR and OS | Smith et al. [94] | Pancreatic | Retrospective | <150 151–300 >300 | Higher PLR correlates with lower OS |
Sakka et al. [95] | Periampullary | Retrospective | 300 | PLR > 300 associated with decreased survival |
Smith et al. [96] | Periampullary | Retrospective | 160 | Higher PLR combined with CA19.9 predicts decreased survival |
Smith et al. [97] | Pancreatic | Retrospective | 150 | PLR useful predictor for tumor resectability (combined with CA 19.9) |
Lee et al. [55] | Gastric | Prospective | 160 | PLR normalization after one cycle of chemotherapy correlates with OS and PFS | He et al. [6] | Colorectal | Retrospective | <150 151–300 >300 | Higher PLR correlates with worse PFS and OS. NLR better prognostic factor than PLR |
Feng et al. [7] | Esophageal | Prospective | 150 | PLR > 150 associated with decreased RFS and OS |
Chua et al. [41] | Appendicular epithelial malignancy | Retrospective | 166 | PLR > 166 associated with lower OS and PFS |
Carrhuters et al. [42] | Rectal | Retrospective | 160 | PLR > 160 associated with lower OS, DFS and TTLR |
Aliostaouglu et al. [26] | Gastric | Retrospective | 160 | PLR < 160 associated with significantly higher survival |
|
|
OS: overall survival; DFS: disease free survival; PFS: progression-free survival; RFS: relapse-free survival; TTLR: time to local recurrence.
|